Investors sold shares of Mednax, Inc (NYSE:MD) on strength during trading on Friday after an insider sold shares in the company. $11.09 million flowed into the stock on the tick-up and $30.84 million flowed out of the stock on the tick-down, for a money net flow of $19.75 million out of the stock. Of all stocks tracked, Mednax had the 0th highest net out-flow for the day. Mednax traded up $1.73 for the day and closed at $43.37Specifically, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.
Several equities analysts have recently weighed in on MD shares. BMO Capital Markets started coverage on shares of Mednax in a research note on Monday, October 16th. They set a “market perform” rating and a $46.00 price target for the company. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Robert W. Baird reaffirmed a “hold” rating and set a $47.00 price target on shares of Mednax in a research note on Sunday, September 3rd. BidaskClub cut shares of Mednax from a “sell” rating to a “strong sell” rating in a research note on Friday, August 4th. Finally, KeyCorp set a $51.00 price target on shares of Mednax and gave the stock a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $54.50.
The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.59 and a current ratio of 1.37. The company has a market cap of $4,061.82, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 1.41 and a beta of 0.32.
Mednax (NYSE:MD) last released its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting the consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. During the same period last year, the business earned $1.09 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. equities research analysts anticipate that Mednax, Inc will post 3.08 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Mednax by 0.3% in the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after buying an additional 28,155 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Mednax by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after buying an additional 38,645 shares in the last quarter. Longview Partners Guernsey LTD grew its stake in shares of Mednax by 10.3% in the second quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after buying an additional 467,845 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Mednax by 22.6% in the second quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after buying an additional 446,074 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its stake in shares of Mednax by 95.9% in the second quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after buying an additional 1,062,584 shares in the last quarter. 99.97% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Investors Sell Mednax, Inc (MD) on Strength Following Insider Selling” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/05/investors-sell-mednax-inc-md-on-strength-following-insider-selling.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.